SL
Therapeutic Areas
Celloram Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CLM-022 | Not Specified (Oncology/Immune/Metabolic Focus) | Preclinical |
| Sopprimerex | Not Specified (Oncology/Immune/Metabolic Focus) | Preclinical |
| NOVS-100 | Not Specified (Oncology/Immune/Metabolic Focus) | Preclinical |
| Protexi | Not Specified (Oncology/Immune/Metabolic Focus) | Preclinical |
Leadership Team at Celloram
TP
Tej Pareek, PhD, MBA, MPH
President, CEO, Board Director
JL
John Letterio, M.D.
Co-founder and Board Director
SK
Seong-Jin Kim, PhD
Co-founder and Board Director
LL
Liraz Levi, PhD
VP and Director Scientific Operations, Small Molecule Program
S(
Sarah (Saerom) Kim
Business Development Advisor